Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $6.00 target price on the stock. Galectin Therapeutics Stock Performance Shares of Galectin Therapeutics stock opened at $2.39 on Tuesday. Galectin Therapeutics […]
HC Wainwright initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $6.00 target price on the stock. Galectin Therapeutics Stock Performance Shares of Galectin Therapeutics stock opened at $2.39 on Tuesday. Galectin Therapeutics […]
